Enanta Pharmaceuticals Inc. has patented compounds acting as nonstructural protein 3 (nsp3, PL-pro; SARS-CoV-2) inhibitors reported to be useful for the treatment of asthma, SARS-CoV-2 infection (COVID-19), rhinovirus, norovirus and lung infections.
Enanta Pharmaceuticals Inc. has divulged macrocyclic chalcone-amide compounds acting as non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors.
Enanta Pharmaceuticals Inc. has disclosed new fused heterobicyclic derivatives reported to be useful for the treatment of hepatitis B virus (HBV) and hepatitis D virus (HDV) infections.
Enanta Pharmaceuticals Inc. has disclosed 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for diseases of the liver.
Enanta Pharmaceuticals Inc. has patented heterocyclic compounds potentially useful for the treatment of metapneumovirus (MPV), influenza and respiratory syncytial virus (RSV) infections.
Recent genome-wide association studies have elucidated a spliced variant (rs72613567:TA) in 17β-hydroxysteroid dehydrogenase 13 (HSD17B13) found to be associated with decreased risk of chronic liver disorders. The presence of this variant also correlates with delayed onset of autoimmune hepatitis in carriers.
Enanta Pharmaceuticals Inc. has synthesized spirocyclic compounds acting as 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
Researchers from Enanta Pharmaceuticals Inc. presented preclinical data for the small molecule non-nucleoside respiratory syncytial virus (RSV) L-protein inhibitor, EDP-323, being developed for the treatment of RSV infection.
Enanta Pharmaceuticals Inc. has presented heterocyclic compounds reported to be useful for the treatment of respiratory syncytial virus (RSV) and metapneumovirus (MPV) infections.
